



Targeted Protein Degradation (TPD): Advancement and Applications

Yancheng Wu

20.10.2020

Why investigate TPD?

Research tool

CRISPR-Cas9/ RNAi :

- a. Days or weeks are required when knockout or knockdown.
 - b. Genetic manipulation generally affects all protein copies.
 - c. Protein depletion is indirect and dependent on the inherent turnover of the protein.
 - d. May have enough time to activate compensatory mechanisms, which may mask phenotypes
-

TPD:

- a. Depletes the target proteins in minutes to hours.
- b. Targeting proteins directly allow certain protein variants to be selectively degraded.
- c. Reversible, more fine-grained control.

Why investigate TPD?

Therapeutic strategy

Traditional drugs:

Limited by the requirements of specific measurable functions of the target protein and accessible binding sites whose occupancy directly influences their function.

Gene therapy:

They are large biomolecules, the gene therapy reagents are difficult to deliver, especially for neurological disease

TPD:

Provides powerful tools to degrade undruggable targets.

Why investigate TPD?

e.g. Proteinopathies

Proteins structurally abnormal, lose their function.

Toxic in some way, disrupt the function of cells, tissues and organs of the body.

Approach for these diseases treatment:

Lowering the levels of disease-causing proteins.

Challenging:


How to specifically eliminate the abnormal protein but do not disturb the wild-type one.

--Achieved by TPD

How is TPD implemented?


Mechanism of TPD—Degradation pathway

The ubiquitin-proteasome system (UPS)



Mechanism of TPD—Degradation pathway

The Autophagy Lysosomal Pathway (ALP)




LC3: The autophagosome protein microtubule-associated protein

1A/1B light chain 3

Bingol B., Mol Cell Neurosci, 2018

How is the substrate recruited— Small Molecule-Induced Selective Protein Degradation



ASO: Antisense oligonucleotides

HyT: Hydrophobic tagging

POI: Protein of interest

CEBN: Cereblon


VHL: Von Hippel Lindau

cIAP: Cellular inhibitor of apoptosis protein

PROTAC: Proteolysis-targeting chimera

How is the substrate recruited—

Emerging New Concepts of Small Molecule-Induced Protein Degradation



LYTAC: Lysosome targeting chimera

AUTAC: The autophagy-targeting chimera

ATTEC: Autophagosome-tethering compound

M6P: mannose-6-phosphate

RESEARCH ARTICLE




Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai, Frank Mercurio, Craig M. Crews, and Raymond J. Deshaies


PNAS July 17, 2001 98 (15) 8554-8559; <https://doi.org/10.1073/pnas.141230798>

Communicated by Alexander Varshavsky, California Institute of Technology, Pasadena, CA (received for review March 29, 2001)

The first example of using chimeric molecules to redirect the specificity of a ubiquitin ligase toward a target protein of interest



(A) PROTAC-1 targets methionine aminopeptidase-2 (MetAP-2) to Skp1-Cullin-F box complex containing Hrt1 (SCF)




IPP: IκBα phosphopeptide

(B) The synthesis scheme for PROTAC-1

MetAP-2 Specifically Binds Protac-1 in Vitro

A.

| | | | | | | | |
|-----|---|---|---|---|---|---|---|
| IPP | - | - | - | - | - | + | - |
| OVA | - | - | - | - | - | - | + |




0 10pM 10nM 10 μ M 10mM

Protac-1

B.

| | | | | | |
|---|---|---|---|---|---|
| - | - | + | - | + | - |
| - | - | - | + | - | + |




0 10 μ M


Protac-1

— MetAP-2-Protac-1
— MetAP-2

Protac-1 recruits MetAP-2 to SCF β -TRCP





Protac mediates MetAP-2 ubiquitination by SCF.




Autocalyzed
cleavage


Full length



MetAP-2-Protac is degraded in Xenopus Egg extracts



General application principle of PROTACs



Conclusions

Proteasomes may be useful research tools for manipulating the phenotype of cells by means of the targeted elimination of specific proteins.


A useful therapeutic agent for targeting the elimination of disease-promoting proteins.

An obstacle to realizing these goals, however, is that the phosphopeptide containing Proteasome-1 described here is unlikely to penetrate cells.

Cell

A Method for the Acute and Rapid Degradation of Endogenous Proteins

Graphical Abstract




Authors

Dean Clift, William A. McEwan,
Larisa I. Labzin, Vera Konieczny,
Binyam Mogessie, Leo C. James,
Melina Schuh

Correspondence

dclift@mrc-lmb.cam.ac.uk (D.C.),
lcj@mrc-lmb.cam.ac.uk (L.C.J.),
melina.schuh@mpibpc.mpg.de (M.S.)


Acute Degradation of Proteins by Trim-Away



NIH 3T3 cells


Trim-Away Degrades Diverse Cellular Substrates

Mammalian oocytes—post-mitotic, transcriptionally silent




Also histone H2B and nuclear localization signal (NLS), data not show

Trim-Away Is Suitable to Degrade Long-Lived Proteins Acutely






Rec8 is part of the cohesin protein complex that mediates sister chromatid cohesion in oocytes from birth until ovulation. Rec8 does not turnover but remains stably associated with chromosomes for months in mice and possibly decades in humans.


Trim-Away Is Suitable to Degrade Long-Lived Proteins Acutely



Trim-Away using antibody electroporation is compatible with quantitative analysis of cellular phenotypes




Trim-Away using antibody electroporation is compatible with quantitative analysis of cellular phenotypes




Pericentrin is proposed to have an important role in the localization of Cdk5rap2 to the centrosome. RNAi/gene knockout are impossible to distinguish between a role for pericentrin in Cdk5rap2 recruitment during the course of the centrosome cycle or in maintenance of Cdk5rap2 at the centrosome.

Selective Trim-Away of Signaling Pathway Components

A



B



Advantages

First, it allows protein function to be studied in non-dividing primary cells where DNA- and RNA-targeting methods are not suitable

Second, it allows the functional analysis of long-lived proteins that are resistant to current knockdown methods that rely on protein turnover.

Third, removal of essential endogenous proteins can now be achieved without the introduction of protein modifications such as degrons.

Fourth, the remarkable speed of Trim-Away means that phenotypes can be observed immediately following degradation of the endogenous protein at any stage of a particular biological process.

Finally, aberrant protein expression or activation is a hallmark of many human diseases such as neurodegeneration and cancer.

Article | Published: 30 October 2019

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds



Zhaoyang Li, Cen Wang, Ziyang Wang, Chenggang Zhu, Jie Li, Tian Sha, Lixiang Ma, Chao Gao, Yi Yang, Yimin Sun, Jian Wang, Xiaoli Sun, Chenqi Lu, Marian Difulgia, Yanai Mei, Chen Ding, Shouqing Luo, Yongjun Dang, Yu Ding , Yiyang Fei  & Boxun Lu 

Nature **575**, 203–209(2019) | [Cite this article](#)


80k Accesses | **24** Citations | **258** Altmetric | [Metrics](#)

Example for autophagosome-tethering compound strategy


Identification of mHTT-LC3 linker compounds



nucleophile-isocyanate reaction




OI-RD: scanning oblique-incidence reflectivity difference




on and off rates (K_{on} and K_{off} , respectively), dissociation constants (K_d)


Linkers induced allele-selective mHTT lowering







Similarities: contain an aryl ring connected to a lactam-based bicyclic structure with halogen-substituted aryl group.

dCultured primary cortical neurons (*Hdh*^{Q7/Q140})

mHTT-LC3 linker compounds lower mHTT in fibroblasts from patients with HD




Using homologous time-resolved fluorescence (HTRF) assay






Linkers tether mHTT to autophagosomes

a




b





Linker compounds rescued HD-relevant phenotypes in vivo



Advantages and Limitations of PROTAC and Emerging Degradation Technologies

| Degradation technology | Degradation pathway | Potential targets | Advantages | Limitations |
|------------------------|--|--|---|--|
| PROTAC | Proteasome pathway | Intracellular proteins | Well established with structural information; clear mechanisms of action; relatively high selectivity; catalytic and sub-stoichiometric | E3-, ubiquitination-, and proteasome-dependent; generally undesirable pharmacokinetic profile; possible limitations of target spectrum |
| LYTAC | Endosome/lysosome pathway for degradation of glycosylated proteins | Extracellular proteins; transmembrane proteins | Applicable to extracellular and transmembrane proteins; independent of ubiquitination and proteasomal degradation | Large molecular weight and poor permeability; possible induction of immune response <i>in vivo</i> |
| AUTAC | Selective macroautophagy pathway | Intracellular proteins; damaged organelles associated with specific proteins | Potentially a broad target spectrum; proteasome-independent; demonstrated ability to degrade mitochondria | Lack of key information of mechanisms of action; dependent on K63 ubiquitination; possible influence on selective autophagy |
| ATTEC | Macroautophagy pathway | Intracellular proteins; non-protein autophagy substrates | Potentially a broad target spectrum; direct targeting to the degradation machinery; potentially effective in all cell types; low molecular weight | The LC3-bound chemical moieties need to be solved; lack of studies on designed chimeras |

THANKS for you attention!